CB 1158

Drug Profile

CB 1158

Alternative Names: CB-1158; INCB 001158; INCB 01158

Latest Information Update: 10 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mars Symbioscience
  • Developer Calithera Biosciences
  • Class Antineoplastics; Immunotherapies; Small molecules
  • Mechanism of Action Arginase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 25 Oct 2017 Incyte Corporation plans a phase I/II trial for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in USA, Belgium and United Kingdom (PO) in December 2017 (NCT03314935)
  • 05 Jun 2017 Pharmacodynamics and adverse events data from a phase I trial in Solid tumours presented at the American Society of Clinical Oncology Annual Meeting (ASCO-2017)
  • 02 Jun 2017 Pharmacokinetics and adverse events data from a phase I trial in Solid tumours presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top